The Swiss pharmaceutical BioVersys has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. The company intends
Tags :Robert von Rosen
Cawood Scientific Limited, the UK based independent provider of analytical testing and sampling services for land-based industries, has tripled the size of its research business through the acquisition of Innovative Environmental Services (IES), an independent
Private investment company Drs Investment sells 100 per cent of the shares in the Swiss software company Xelog to Prologistik Holding. The acquisition of Xelog, the Swiss logistics software specialist, is part of Prologistik’s strategy
Walder Wyss acted as legal counsel to Dr. Wild & Co., the Swiss family-owned pharmaceutical manufacturer, on the sale of its Pharma business, including its product portfolio in Vitamin D and other well-known products, to
Walder Wyss advises Boehringer Ingelheim. The team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured left) and Robert von Rosen (Partner, Corporate/M&A and Venture Capital). VISCHER advised
VISCHER is advising Noema Pharma in this transaction. The team is led by Matthias Staehelin (Corporate, pictured left). Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors. The team included
The team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured), Robert von Rosen (Partner, Corporate/M&A and Venture Capital) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).
The team was led by Alexander Gutmans (Partner, Transaction/M&A & Venture Capital) and Robert von Rosen (Partner, Transaction/M&A & Venture Capital) and included Ayesha Curmally (Partner, Notary Services), Jessica Aeschbach Flórez (Senior
The team was led by partner Alexander Gutmans (Transaction/M&A & Venture Capital - pictured) and partner Robert von Rosen (Transaction/M&A & Venture Capital)
